Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 29, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On August 25, 2006, there was an increase in the notional allocation of Ordinary Share ADRs at a price of $54.55 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Date: August 25, 2006.
- Notification Date: August 29, 2006.
- Share Price: $54.55 per ADR.
- Involved Parties: Dr. M M Slaoui (8 shares) and Dr. R Greig (3 shares).
- Plan Type: US Retirement Savings Plan (notional investment in GSK Ordinary Share ADRs).